Search > Cancer
My employer runs this trial

LY4336619 for Cancer

Not yet recruiting at 22 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Eli Lilly and Company
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.

Who Is on the Research Team?

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This trial is for adults with advanced cancers such as endometrial, ovarian, germ cell, non-small cell lung, or stomach cancer. Participants should be able to tolerate treatment and meet specific health requirements set by the study team.

Inclusion Criteria

Have a life expectancy of at least 12 weeks as judged by the investigator
I have been diagnosed with an advanced or metastatic solid tumor.
I cannot use standard treatments, or they no longer work or are not safe for me.
See 1 more

Exclusion Criteria

I have or had a brain or nervous system disease like stroke or epilepsy.
I still have nerve-related symptoms from past CAR-T or bispecific treatments.
I have serious heart or blood vessel disease.
See 4 more

What Are the Treatments Tested in This Trial?

Interventions

  • LY4336619
  • Sofetabart Mipitecan (Sofe-M)

Trial Overview

The study is testing a new drug called LY4336619 alone or combined with another medicine (Sofetabart Mipitecan) to see how safe and effective they are in treating advanced solid tumors. Treatment can last up to 2 years.

How Is the Trial Designed?

4

Treatment groups

Experimental Treatment

Group I: LY4336619 and Sofetabart Mipitecan (Sofe-M) CombinationExperimental Treatment2 Interventions
Group II: LY4336619 Dose OptimizationExperimental Treatment1 Intervention
Group III: LY4336619 Dose ExpansionExperimental Treatment1 Intervention
Group IV: LY4336619 Dose EscalationExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.